| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e77f06144be4708a6ae75bd9fee56a4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-52 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00 |
| filingDate |
1985-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1996-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb361a79dac59706d952830bc62fe3a2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e53ae24fcae7c6746b3e3261bb469476
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6df7d41984b261003bb57576cfe8b962
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0842967aea4f6f68a9ff50bd4098acd4 |
| publicationDate |
1996-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
DK-170781-B1 |
| titleOfInvention |
Human leukoregulin and biologically active subunits thereof, method of preparation and purification of human leukoregulin, biologically active material containing human leukoregulin and cell producing human leukoregulin |
| abstract |
(1) Leukoregulin (I) in pure form and its biological sub-units are new. It regulates the physiology and growth of malignant tumour cells without affecting the growth of normal cells. (I) directly lyses tumour cells; it suppresses tumour cell proliferation; it enhances the susceptibility of tumour cells to NK cell mediated lysis; it alters tumour cell surface conformation and permeability; and it inhibits the carcinogenic transformation of normal cells. (2) Isolated concd. human (I) having a molecular wt. of 120,000-140,000 and isoelectric focussing points at pH 4.8-5.5 and 7.5-8.3 is new. It is eluted on anion exchange chromatography at 0.07-0.12 M NaCl salt conc. It is partly digested by protease but not by neuraminidase and it produces subunits on dissociation of mol. wt. 30,000-35,000. (3) Biologically active compsn. comprising an effective amt. of (I) is new. (4) Cell producing human (I) and consisting of transformed B cells or hybridoma cells is new. It is obtd. from the peripheral blood of a cancer patient who has been inoculated with a vaccine comprising viable cells from the patient's own tumour, or a culture of the cells. (5) Cells producing human (I) transformed by a transfer vector contg. the gene for (I), or a biologically subunit of it, is new. (6) Monoclonal antibody specific for (I) cell surface receptor is new. (7) Hybridoma producing the monoclonal antibody defined above is new. (8) (I) or its subunit is used in a method for treating tumour cells in tissue, the method comprising the ex-vivo exposure of tumour cells. Esp. viable bone marrow cells for use in reconstituting a patient's bone marrow are first exposed to (I) or its subunit. |
| priorityDate |
1984-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |